• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol.

作者信息

Demirkan Serkan, Gündüz Özgür, Devrim Tuba

机构信息

Department of Dermatology and Venerology, Kirikkale University Faculty of Medicine, Kirikkale, Turkey.

Department of Pathology, Kirikkale University Faculty of Medicine, Kirikkale, Turkey.

出版信息

JAAD Case Rep. 2017 Jul 20;3(4):354-357. doi: 10.1016/j.jdcr.2017.03.017. eCollection 2017 Jul.

DOI:10.1016/j.jdcr.2017.03.017
PMID:28761920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5522952/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/ceec45f96482/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/979e7e32855f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/717228dc8bf7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/ceec45f96482/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/979e7e32855f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/717228dc8bf7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec5/5522952/ceec45f96482/gr3.jpg

相似文献

1
Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol.外用骨化三醇治疗索拉非尼相关的手足综合征。
JAAD Case Rep. 2017 Jul 20;3(4):354-357. doi: 10.1016/j.jdcr.2017.03.017. eCollection 2017 Jul.
2
Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.手足皮肤反应与索拉非尼治疗转移性肾细胞癌患者的临床结局相关。
Jpn J Clin Oncol. 2013 Oct;43(10):1023-9. doi: 10.1093/jjco/hyt110. Epub 2013 Aug 15.
3
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.手足综合征和进展后治疗是索拉非尼治疗晚期肝细胞癌患者生存改善的良好预测指标：一项多中心研究
Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20.
4
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌患者结局的临床预测因素。
Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.
5
Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.索拉非尼治疗晚期肝细胞癌患者的累积剂量增加和手足皮肤反应出现延长无进展生存期。
Kaohsiung J Med Sci. 2018 Jul;34(7):391-399. doi: 10.1016/j.kjms.2018.03.006. Epub 2018 Apr 4.
6
Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.在未调整剂量的情况下，维生素E治疗肝细胞癌患者索拉非尼所致手足综合征的初步临床研究
J BUON. 2011 Oct-Dec;16(4):759-64.
7
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.治疗前血浆脂质组学分析揭示索拉非尼治疗患者的反应率和手足皮肤反应相关的生物标志物候选物。
Cancer Chemother Pharmacol. 2018 Oct;82(4):677-684. doi: 10.1007/s00280-018-3655-z. Epub 2018 Jul 30.
8
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.多激酶抑制剂相关手足皮肤反应可预测索拉非尼治疗肝细胞癌患者的结局。
World J Gastroenterol. 2018 Jul 28;24(28):3155-3162. doi: 10.3748/wjg.v24.i28.3155.
9
β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.补充β-羟基-β-甲基丁酸/L-精氨酸/L-谷氨酰胺预防索拉非尼治疗晚期肝细胞癌时的手足皮肤反应
In Vivo. 2019 Jan-Feb;33(1):155-161. doi: 10.21873/invivo.11452.
10
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.HATT：一项在台湾晚期肝细胞癌患者中开展的索拉非尼的IV期单臂开放标签研究。
Hepatol Int. 2017 Mar;11(2):199-208. doi: 10.1007/s12072-016-9774-x. Epub 2016 Dec 1.

引用本文的文献

1
Sorafenib Induced Hand-Foot Skin Reaction at Low Dose.低剂量索拉非尼诱发的手足皮肤反应
Indian Dermatol Online J. 2020 Sep 19;11(6):997-1000. doi: 10.4103/idoj.IDOJ_115_20. eCollection 2020 Nov-Dec.
2
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.癌症治疗引起的皮肤不良反应管理：专家小组建议
An Bras Dermatol. 2020 Mar-Apr;95(2):221-237. doi: 10.1016/j.abd.2020.01.001. Epub 2020 Feb 15.
3
Dermatologic conditions in women receiving systemic cancer therapy.接受全身性癌症治疗的女性的皮肤病状况。

本文引用的文献

1
Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.抗肿瘤血管生成治疗的皮肤表现：以 VEGF 抑制剂为重点的综述。
Crit Rev Oncol Hematol. 2014 May;90(2):152-64. doi: 10.1016/j.critrevonc.2013.11.007. Epub 2013 Dec 1.
2
Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.多激酶抑制剂索拉非尼和舒尼替尼的皮肤毒性。
Dermatol Ther. 2011 Jul-Aug;24(4):396-400. doi: 10.1111/j.1529-8019.2011.01435.x.
3
Drug therapy: sorafenib.药物治疗：索拉非尼。
Int J Womens Dermatol. 2019 Nov 7;5(5):285-307. doi: 10.1016/j.ijwd.2019.10.003. eCollection 2019 Dec.
Hepatology. 2010 May;51(5):1843-9. doi: 10.1002/hep.23676.
4
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.接受多靶点激酶抑制剂索拉非尼和舒尼替尼治疗的患者的皮肤不良反应。
Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.
5
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.银屑病和银屑病关节炎管理的护理指南。第3节。外用疗法治疗银屑病的护理指南。
J Am Acad Dermatol. 2009 Apr;60(4):643-59. doi: 10.1016/j.jaad.2008.12.032. Epub 2009 Feb 13.
6
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
7
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.与多激酶抑制剂索拉非尼相关的皮肤症状。
J Am Acad Dermatol. 2009 Feb;60(2):299-305. doi: 10.1016/j.jaad.2008.06.034. Epub 2008 Nov 25.
8
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.与多靶点激酶抑制剂索拉非尼和舒尼替尼相关的手足皮肤反应的管理策略进展
Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8.
9
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
10
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.新型多激酶抑制剂索拉非尼皮肤不良反应的前瞻性研究。
Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.